IFS Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

IFS Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200	Closed	-$7.55K	–	130
2022 Q4	$7.55K	Hold	200	–	–	0.01%	64
2022 Q3	$8K	Hold	200	–	–	0.01%	53
2022 Q2	$7K	Hold	200	–	–	0.02%	56
2022 Q1	$7K	Hold	200	–	–	0.01%	69
2021 Q4	$6K	Buy	+200	New	+$6.29K	﹤0.01%	83
2021 Q1	–	Sell	-200	Closed	-$11K	–	79
2020 Q4	$11K	Buy	+200	New	+$9.97K	0.01%	99

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

IFS Advisors's IONS Position: Q1 2023 in Review

IFS Advisors sold out of Ionis Pharmaceuticals (IONS) in Q1 2023, closing a stake of 200 shares — an estimated $7.55K sold.

IFS Advisors first reported a position in IONS in Q4 2020 and held it in 6 quarters. The position peaked at $11K in Q4 2020. 313 funds tracked by Wall St. Rank hold IONS as of Q1 2023.

IFS Advisors reported no remaining Ionis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
IFS Advisors sold 200 Ionis Pharmaceuticals shares in Q1 2023, an estimated $7.55K.
IFS Advisors first reported a position in Ionis Pharmaceuticals in Q4 2020 and held it in 6 quarters.
IFS Advisors's Ionis Pharmaceuticals position peaked at $11K in Q4 2020.
313 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2023.

Based on IFS Advisors's 13F filing for Q1 2023, filed 2 May 2023.